Navigation Links
Hospira Shares Results From Two Open-label Extension Studies for Biosimilar Infliximab in Patients With Rheumatoid Arthritis or Ankylosing Spondylitis
Date:10/31/2013

ETRA (Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in RA Patients)
PLANETRA was a prospective, randomized, double-blind, multicenter, parallel-group, Phase III trial that evaluated CT-P13 (infliximab) biosimilar product relative to the Remicade (infliximab) reference product in 606 patients with active rheumatoid arthritis who were not receiving adequate response to methotrexate alone over at least 3 months. The primary objective of the study was to demonstrate efficacy equivalence between CT-P13 and Remicade groups up to Week 30, as determined by clinical response according to the American College of Rheumatology (ACR) definition of a 20% improvement (ACR20). Secondary objectives of this study were to evaluate long-term efficacy, pharmacokinetics, pharmacodynamics, and overall safety of CT-P13 in comparison with Remicade up to Week 54.

PLANETRA is registered on ClinicalTrials.gov and can be accessed at: http://www.clinicaltrials.gov/ct2/show/NCT01217086?term=ct-p13&rank=4

About PLANETAS (Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients)
PLANETAS was a prospective, randomized, double-blind, multicenter, parallel-group Phase I trial which evaluated CT-P13 (infliximab) biosimilar product relative to the Remicade (infliximab) reference product in 250 patients with active ankylosing spondylitis. The primary objective of this study was to demonstrate comparable pharmacokinetics at steady state between CT-P13 and Remicade groups up to Week 30, as measured by area under the concentration-time curve over a dosing interval (AUC) and observed maximum serum concentration at steady state (Cmax,ss). Secondary objectives of this study were to assess the long-term efficacy, pharmacokinetics, and overall safety of CT-P13 in comparison with Remicade for up to Week 54.

PLANETAS is registered
'/>"/>

SOURCE Hospira, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Hospira Unveils New Quality Laboratory and Investments at Rocky Mount, N.C., Plant
2. Hospira Launches Q Core Sapphire Infusion System in the United States
3. Gastroenterologists Unlikely To Use Celltrion/Hospiras Infliximab Biosimilar Due To Lack Of Clinical Data In Inflammatory Bowel Disease
4. Hospira to Present at the Morgan Stanley Global Healthcare Conference
5. Hospira Data on European Biosimilar Epoetin, Retacrit, Affirm Treatment Response, Tolerability in Management of Anemia Secondary to Chemotherapy
6. Amgen, Hospira and Sandoz Named Among Top Pharmaceutical Companies with Greatest Biosimilar Drug Potential in United States
7. Hospira dévoile sa stratégie appareil mondiale
8. Hospira enthüllt weltweite Gerätestrategie
9. Hospira revela estrategia global para sus dispositivos
10. Hospira revela estratégia global para dispositivos
11. Hospira Reports First-Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... market has witnessed robust development with the growth pace keeping ... starter. In 2012, the size of China ... proportion worldwide soaring to 16.3%. It is projected that ... growth rate by around 20% in the upcoming years and ... billion. An integrated membrane industrial system has taken ...
(Date:12/17/2014)... , Dec. 17, 2014  Strategic Health Services, ... software solutions, today announced a strategic agreement with QualCare, ... New Jersey regional marketplace.  This agreement ... the health and wellness solutions QualCare brings to its ... the surrounding region. QualCare plans cover ...
(Date:12/17/2014)... -- , The new Dompé ... information concerning the biopharmaceutical Group,s national and international clinical research ... the recently launched institutional website that is receiving accolades from ... a new chapter in the fascinating story of Drug Discovery ... panoramic hub on the world of clinical research, ranging from ...
Breaking Medicine Technology:Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3
... 2012 Reportlinker.com announces that a new ... catalogue:   ... Devices http://www.reportlinker.com/p0799254/Pricing-and-Reimbursement-Strategies-for-Medical-Devices.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Facility ... medical devices being purchased within public healthcare ...
... Therapeutics, LLC, a clinical-stage biopharmaceutical company developing novel ... the TREAT-NMD Advisory Committee on Therapeutics (TACT) has ... dystrophy (DMD), and believes the compound has potential ... global network dedicated to expediting the delivery of ...
Cached Medicine Technology:Pricing and Reimbursement Strategies for Medical Devices 2Pricing and Reimbursement Strategies for Medical Devices 3Pricing and Reimbursement Strategies for Medical Devices 4Halo Therapeutics Reports Favorable Independent Review of Lead Drug Candidate HT-100 2Halo Therapeutics Reports Favorable Independent Review of Lead Drug Candidate HT-100 3
(Date:12/19/2014)... 20, 2014 The print component of ... Business subscription of the Toronto Star, with a circulation ... 622,169. The digital component is distributed nationally through a ... top news sites and partner outlets. To explore the ... , The publication features an exclusive interview with ...
(Date:12/19/2014)... FRIDAY, Dec. 19, 2014 (HealthDay News) -- All children ... 3 and 6, preferably every year, eye experts say. ... from an expert panel of the U.S. National Center ... children in this age group require screening for eye ... glasses, such as amblyopia ("lazy eye") and strabismus (a ...
(Date:12/19/2014)... of bacteria called biofilms can be found on most colon ... researchers said these biofilms were especially prevalent on the right ... may represent an increased likelihood of colon cancer and could ... the disease, the researchers said. Like tooth plaque and ... layer of cells lining the colon, according to background information ...
(Date:12/19/2014)... Surviving Mesothelioma says thousands of water pipes in ... pipes can leach asbestos into drinking water as they age. ... on the Surviving Mesothelioma website. , According to the ... decaying water mains made of asbestos cement are the major ... protect consumers from mesothelioma , water providers are subject to ...
(Date:12/19/2014)... B. E. Smith, the only full-service leadership ... retained to lead a national chief financial officer ... Park, Colo. The top executive search firm in the ... than 900 healthcare executives into organizations. , Estes ... access hospital and level IV trauma center, with a ...
Breaking Medicine News(10 mins):Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2Health News:Preschoolers Need Eye Screening, Experts Say 2Health News:Could Bacteria Play a Role in Colon Cancer? 2Health News:Surviving Mesothelioma Warns of Potential Mesothelioma Risk from Cement Water Pipes 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3
... to people suffering from chronic lower back pain, as physical ... same amount of physical relief // has been reported by ... who did not undergo any treatment at all. A combination ... by way of relief. ,Dr. Rob Smeets ...
... over a case lodged by a wife against her ex-husband (diagnosed ... virus. Apparently, he had not disclosed his HIV positive // status ... others at risk of HIV infection over a period of 6 ... to have had unprotected sex with her partner nealry 5 times ...
... conducted at the State University of New Jersey (Rutgers) ... isothiocyanate (PEITC) is very effective in the treatment of ... in cauliflower, cabbage, watercress, winter cress, broccoli, Brussels sprouts, ... turmeric (curcumin), alone or in combination is very effective ...
... come out in support of the Health Minister on the ... to prescribe in Wales. The move has been widely criticized, ... ,"GPC Wales welcomes the statement of the Health Minister ... Doctors are highly trained professionals who should be able to ...
... are born to women who eat more fish when pregnant ... to other children. This is because the omega-3 fatty acids ... study conducted by the National Institutes //of Health, Bethesda, Maryland. ... the child's intelligence, fine motor skills, the ability to manipulate ...
... fighters will be honored with “Honor Roll of Life” for ... two Fire fighters John Jensen and Joe Kazlauskas donated their ... leukemia patients which helped to save their life. ... as the department offices have donated more than 72 bone ...
Cached Medicine News:
Single use trocar with non-conductive sleeves for gaining and maintaining thoracic access., ,THORACOPORT™ devices are trocars used to gain access to the thoracic cavity for use in video assis...
These are the Reusable Components (minus cannula), to be used with the VersaStep™ Plus Reposable Short System....
The VersaStep™ 5 mm and VersaStep™ PLUS Reposable system components for creating each access port are supplied in separate packages....
VersaStep™ Reposable Sterilization Trays....
Medicine Products: